Results 221 to 230 of about 21,799 (237)

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

Annals of the Rheumatic Diseases, 2017
Dae-Hyun Yoo, Piotr Wiland, Carlos Abud-Mendoza   +2 more
exaly  

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Annals of the Rheumatic Diseases, 2017
Bente Glintborg, Anne Gitte Loft, Oliver Hendricks   +2 more
exaly  

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

The Lancet Gastroenterology and Hepatology, 2018
Anne S Strik, M T Nurmohamed, Peter Bossuyt   +2 more
exaly  

Biosimilars.

PDA journal of pharmaceutical science and technology, 2016
  +5 more sources

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study

Annals of the Rheumatic Diseases, 2017
Stanley B Cohen, Mark C Genovese, Ernest H Choy   +2 more
exaly  

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

Annals of the Rheumatic Diseases, 2019
Bente Glintborg, Anne Gitte Loft, Oliver Hendricks   +2 more
exaly  

Biosimilarity

2018
openaire   +2 more sources

Postmarket policy considerations for biosimilar oncology drugs

Lancet Oncology, The, 2016
Matthew J Renwick, Kate Smolina, Emilie J Gladstone   +2 more
exaly  

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

Annals of the Rheumatic Diseases, 2018
Josef S Smolen, Jung-Yoon Choe, Roman Yatsyshyn   +2 more
exaly  

Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial

The Lancet Gastroenterology and Hepatology, 2018
Igor N Bondarenko, Vikas Ostwal Dm, Ana Del Campo García   +2 more
exaly